VIDEO: Exploring available treatment options in DME

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There's a variety of different options for diabetic macular edema. We've been very fortunate to have anti-VEGF therapy for the past 15 years, for this condition. It's really been transformative. It's improved vision, it's caused less legal blindness in the United States, as a result of the therapy, so really a huge advantage to our population. The limitations of this, we're really quite aware. It requires frequent therapy, frequent monitoring. The durability is questionable, and so those are some of the drawbacks of anti-VEGF therapy, and we've also relied on steroids. Steroids have also been an advent for us to treat patients for DME. Again, very good options for patients, but also, with a side effect profile that is well-known, with cataracts and glaucoma being the primary ones for that. More recently, we've had the approval of Foricimab, which is the first dual-agent, bispecific molecule for diabetic macular edema. This is both an Ang 2 and an anti-VEGF inhibitor and Ang 2 does play a significant role in these disease pathogenesis, as we know, and therefore offers a more potential durable option, with a significant advantages, over the current anti-VEGF therapies we have available to us today.